Reviewed by Dr Sarah Mitchell, PhD · Editorial Board
Saxenda in the UK — patient guide
Saxenda is the Novo Nordisk liraglutide brand licensed for weight management. Once the standard prescribed GLP-1 for obesity in the UK, it has been largely superseded by Wegovy and Mounjaro — but it remains in use for patients who tolerate it well or who can't access the newer products.
What Saxenda is
Saxenda is liraglutide presented for chronic weight management. Liraglutide is a once-daily injectable GLP-1 receptor agonist first licensed in 2009 (for type 2 diabetes as Victoza); the Saxenda weight-management licence followed.
Dose schedule
- Week 1: 0.6 mg daily
- Week 2: 1.2 mg daily
- Week 3: 1.8 mg daily
- Week 4: 2.4 mg daily
- Week 5+: 3.0 mg daily (maintenance)
Titration steps can be extended where nausea is intolerable. The daily injection schedule is the main practical difference from the newer once-weekly GLP-1s; some patients find the daily routine easier, others find it harder.
Why uptake has fallen
- Trial-effect size. Mean weight loss on Saxenda in trials is around 8% at one year — lower than Wegovy (~15%) and Mounjaro (~20–22%).
- Daily vs weekly dosing. Most patients prefer weekly injections.
- NHS pathway alignment. NICE TA875 (Wegovy) and TA1026 (Mounjaro) gave the NHS clearer pathways for the newer products.
Saxenda still has a place where:
- A patient is already well-established on it.
- Wegovy / Mounjaro supply is unavailable.
- An individual tolerates liraglutide better than the newer agents.
- A clinician chooses it for specific clinical reasons.
NHS access
Saxenda has been available on the NHS through specialist weight-management services with eligibility criteria broadly similar to those used for newer GLP-1s (BMI threshold with comorbidity, structured programme participation). Local variation is significant.
Private prescription
Available privately via a GMC-registered prescriber and GPhC-registered pharmacy. Pricing has fallen as the product has aged and demand has shifted to weekly products.
Side effects
Largely the same profile as other GLP-1s: nausea, vomiting, diarrhoea, constipation, decreased appetite. Less common but more serious effects include gallbladder disease and pancreatitis. Daily dosing means the nausea curve through the day is different from weekly products — some patients find this easier (no big trough), others find it harder (no recovery day).
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“Cheap Saxenda — bypass the waiting list”
‘Bypass the waiting list’ implies skipping clinical assessment, which is what makes prescribing lawful.
“Liraglutide research vials — same as Saxenda”
Research-grade liraglutide is unlicensed-medicine supply. Saxenda is the licensed product. Not the same supply chain or quality assurance.
“Push to 4mg daily for better results”
Outside the Saxenda licence (max 3.0 mg). Trial data doesn't support pushing past 3 mg.
Sources & further reading
- MHRA — gov.uk
- NICE TA875 — semaglutide for weight management — nice.org.uk
- NICE TA1026 — tirzepatide for weight management — nice.org.uk
- NHS — obesity treatment — nhs.uk
- Human Medicines Regulations 2012 — legislation.gov.uk